Our Investment in Aspect Biosystems – Pioneering Microfluidic 3D Bioprinting of Human Tissues Raises $20 million Series A for Business Expansion
By Brent MacDonald – Principal @ Rising Tide VC
Aspect Biosystems is a Vancouver-based biotechnology platform company that pioneered a platform using microfluidics and 3D bioprinting to create living, human tissues with control, flexibility, and precision. The Company’s proprietary technology has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine.
Aspect Biosystems is a University of British Columbia spinoff startup founded in 2013. Since then, the company has garnered industry recognition by announcing its ability to use live human cells to create and build living human tissue. View Tamer Mohamed TEDx Talk here.
Aspect Biosystems is partnering with some of the biggest names in industry and is making major breakthroughs in applying its technology to create functional tissues. It has 20+ strategic partners globally, focused on creating high-value solutions. In addition, the Company’s network of academic researchers and industry partners are key to making the Company’s vision a reality.
The Company’s current internal programs are focused on orthopedic and metabolic diseases. On the orthopedic side, Aspect Biosystems is leveraging its knowledge of musculoskeletal biology and biomaterials to create knee meniscal replacements. On the metabolic side, the company is focused on liver tissue and creating a therapeutic tissue for Type 1 Diabetes (T1D). Externally, Aspect Biosystems’ partners around the world are using its 3D bioprinting technology to advance research in the brain, lungs, heart, pancreas, and kidneys, just to name a few.
Why We Are Excited:
By combining microfluidics with 3D printing, Aspect Biosystems is disrupting regenerative medicine. The Company can programmatically process multiple cells and biologically relevant materials in high throughput to rationally design and produce functional tissues. Aspect Biosystems is constantly integrating new microfluidic processing units within their printhead technology and leveraging continuous advancements in the “lab-on-a-chip” space. With their microfluidic 3D bioprinting technology, the company is generating a large amount of data. By using this data and machine learning, Aspect Biosystems is improving the quality and automation of the biomanufacturing process. Ultimately, bioprinting is only as good as the teams understanding of biology – and their understanding of biology is growing wider and deeper. The interdisciplinary team is operating at the cutting edge of science, engineering, medicine, and business with over 30 PhDs and MScs/MDs. Through innovation and talent, Aspect Biosystems is bringing to market revolutionary technologies for strategic applications in the life sciences.
Aspect Biosystems’ most recent Series A $20 million funding round includes Radical Ventures, Pangaea Ventures, Pallasite Ventures, Rhino Ventures and Rising Tide. Aspect Biosystems will use this capital to advance multiple bioprinter therapeutic programs, expand its technology platform capabilities, and grow its world-leading team. Please read the full press release here.
Rising Tide Fund Managers, LLC and its affiliates (“Rising Tide” or “We”) is a United States venture capital firm investing primarily in the information technology and healthcare / life sciences markets. Over the last 35 years, we have partnered with family funds, high-impact investors, and strategic partners to help launch and expand startups in a variety of industries across three continents. We are dedicated to cooperating with our entrepreneurs at all stages: from financing to leveraging our international networks to facilitating exits by design. For more information, visit www.rtf.vc.
The portfolio companies described herein do not represent all the portfolio companies purchased, sold or recommended for portfolios advised by Rising Tide. The reader should not assume that an investment in the portfolio companies identified were or will be profitable. Past performance is not indicative of future results. Investors should be aware that a loss of investment is possible.